Cell Line Development and Antibody Discovery

Dear valued customer

It is our pleasure to invite you to our free Seminar Tour on

New Technologies Streamline Cell Line Development and Antibody Discovery
"Work Smarter Not Harder".

Key Topics

  • Fully Integrated Microfluidics Platform
  • Single Cell Secretion Assay
  • Documented Monoclonality Assurance
  • Correlate IgG Titer with Cell Growth
  • Rank Clones over Hundreds of Plates
  • Optimize, Analyze, Visualize... Faster!

This seminar will be an excellent opportunity to learn about these new technologies and concepts that help streamline your workflow by combining cell- and antibody-based assays in high throughput, fully integrated screening platforms.

Seminar Locations and Dates

  • Basel            –     Monday, 22 October 2018         3:00pm *
  • Schlieren     –     Tuesday, 23 October 2018         9:00am *
The duration of the seminar will be approx. 2 hours.

*)  The exact place of the event will be mentioned in our confirmation

Seminar Agenda / Talks & Topics

Introduction & Overview of the Seminar
  • Accelerate Antibody Discovery and Cell Line Development Workflows with Cyto-Mine
    Xin Liu, PhD, Sphere Fluidics, United Kingdom
  • High Throughput Multiplexed Screening of Cells and Antibodies with the IntelliCyt iQue Screener PLUS
    Kathrin Dienst, PhD, Bucher Biotec AG, Basel, Switzerland
Featured User Presentation
  • Basel:
    Using iQue as a Screening Platform for Antibody Discovery

    Chawaree Chaipan, PhD, Novartis, Basel, Switzerland
  • Schlieren:
    Integration of the iQue Screener Plus Platform in a High Throughput Cell Line Development Workflow
    Julie Frentzel, PhD, Merck Serono SA, Switzerland
Closing Remarks and Discussion


Your participation is free of charge. In order to register for the Seminar, please click below or simply give us a call (phone +41 61 269 1111).

We will confirm your registration with detailed information and exact location of the event.

About the Seminar

Key parameters for the development of therapeutic monoclonal antibodies are the selection of the best antibody and the selection of the best cell line. Traditionally, the determination of both parameters require various items of equipment covering the selection of antibody and cell lines with high secretion levels, isolation and cultivation of single cells, and characterization of antibody binding properties.

While laborious and expensive, those assays are most often restricted to a single read-out, which is not representing the complexity of the physiological context. For example, selection of cells based on surface staining may not represent the whole process of antibody secretion and lacks the possibility of monitoring the single cell dispension. An immunosorbent assay cannot provide information about cross-reactivity and is limited to recombinant proteins. Recent advances in assay technology are beginning to transform the therapeutic monoclonal antibody discovery process. At the center of these advances is the ability to perform multiplexed, multiparameter assays at high throughput screening speeds.

The selection and isolation of a cell line can now be combined in a single assay. Here, the secreted antibody can be quantified from cell culture medium, while the secreting cell can be dispensed into microtiter well plates with monoclonality assurance.

Analysis of antibody specificity and cross-reactivity have long been established using flow cytometry, which allows multiplexed assays to compare binding to different antigens or to competition between binding to recombinant proteins or to cellular surfaces. Within the last decade, the high throughput capacities of classical flow cytometers have dramatically increased and are now empowering HT-screening.

Who should attend?

We would like to invite everyone interested in learning about and utilizing cutting edge technology for fully integrated screening platforms. You will enjoy a unique opportunity to interact with your colleagues, the speakers and with fellow researchers from academic and industrial institutions.

Sphere Fluidics – Cyto-Mine®

Sphere Fluidics Cyto-Mine
In the Cyto-Mine system, single cells are encapsulated in a growth media containing picodroplet, which thereby acts as a bioreactor compartmentalizing the cell. Cell cultivation within the droplet allows for rapid selection of relevant single cells based on their secreted molecules, such as antibodies. Hit selection is handled flexible, e.g. antigen- or isotype-specific selection combined with secretion level of the targets. Cell dispension into microtiter plates is combined with imaging for monoclonality assurance.

Sphere Fluidics’ Cyto-Mine technology is the first integrated device to automatically perform all of these steps in a single compact system with animal origin free consumables, hence minimizing effort, costs, lab space, and risk of sample contamination.

IntelliCyt, A Sartorius Brand – iQue® Screener PLUS

IntelliCyt iQue PLUS Screener
The iQue Screener is a high throughput screening platform based on flow cytometry, that most rapidly processes samples in suspension. The unique sampling method allows for screening of cells and beads at the same time. Via dye encoding, multiple populations of cells or beads bearing different antigens of interest can be combined in the wells to screen for multiple target antigens in a single experiment. This greatly increases the power and robustness of antibody screening campaigns.

Additionally, the Cy-Clone PLUS Kit offers a multiplexed assay that simultaneously reports on IgG quantity, cell number, and cell viability in each well. These metrics enable the precise calculation of the IgG quantity per cell and per viable cell, which are relevant criteria for the selection of a best clone.

IntelliCyt Cy-Clone PLUS Kit


Your participation is free of charge. In order to register for the Seminar, please click below or simply give us a call (phone +41 61 269 1111).

We will confirm your registration with detailed information and exact location of the event.